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The ‘‘Side Population’’ (SP) discrimination assay is a flow cytometry method used to detect stem cells based
on the dye efflux properties of ABC transporters. We discuss the SP assay and its applications in stem
cell biology, with an emphasis on the technical challenges related to sample preparation, data acquisition,
analysis, and interpretation. We highlight the value of multicolor phenotyping, the impact of DNA ploidy,
and the importance of distinguishing graft versus host cells for an appropriate SP discrimination. To improve
the consistency and reliability of data between laboratories, we propose a set of recommendations for SP
assay data reporting.The Side Population (SP) discrimination assay is based on the
differential potential of cells to efflux the Hoechst dye via
the ATP-binding cassette (ABC) family of transporter proteins
expressed within the cell membrane. ABC transporters belong
to the superfamily of membrane pumps that catalyze ATP-
dependent transport of various endogenous compounds and
xenobiotics out of the cell. Following sequencing of the human
genome, it has been estimated that between 500 and 1200
genes encode drug transporters (Venter et al., 2001). ABCB1
(P-glycoprotein, MDR1), ABCC1-5 (multidrug-resistant proteins,
MRP1-5), and ABCG2 (breast cancer resistance protein, BRCP1)
are the best-characterized transporter proteins that function to
establish the SP phenotype (Robey et al., 2009; Schinkel and
Jonker, 2003; Sun et al., 2003; Zhou et al., 2001).
The ability of ABC transporters to rapidly efflux lipophilic
fluorescent dyes in vitro serves as the basis of the SP assay,
which was first described using mouse bone marrow cells
(Goodell et al., 1996). The bone marrow SP has been shown to
be highly enriched for functional hematopoietic stem cells
(HSCs) and also overlaps with the phenotypically defined
CD117+Sca-1+LinThy1lo HSC population (Camargo et al.,
2006; Challen et al., 2010). Indeed, combining SP determination
with cell-surface marker phenotyping leads to efficient, reliable
characterization of the HSC subset, and HSCs isolated accord-
ing to these combined traits are one of the most pure and potent
adult stem cell populations available.
Since its development more than 15 years ago, the SP assay
has emerged as a promising method for identifying stem cell
and progenitor populations in different tissues, including umbil-
ical cord blood (Storms et al., 2000), skeletal muscle (Asakura
et al., 2002; Gussoni et al., 1999), kidney (Iwatani et al., 2004),
liver (Shimano et al., 2003), mammary glands (Clayton et al.,
2004), lung (Summer et al., 2003), and forebrain (Kim and Mors-
head, 2003). Importantly, stem cells that exhibit SP properties
are rare in most tissues and often constitute a heterogeneous
population, differing with organ type and stage of development.
Although SPs are clearly enriched in stem cells, several reports136 Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc.caution that dye efflux is not a common property of all stem
cell populations (Terunuma et al., 2003; Triel et al., 2004; Zeng
et al., 2009). Moreover, the SP phenomenon is not restricted to
the stem cell phenotype because it has also been described in
certain differentiated cells in adult tissues. Indeed, ABC trans-
porters are expressed by specialized cells in several organs,
including small intestine (Mayer et al., 1996), liver, kidney (Smit
et al., 1998), brain microvessel endothelial cells (Schinkel,
1999), epithelial cells of blood-cerebrospinal fluid barrier (Segal,
2000), blood-testis barrier (Choo et al., 2000), and placenta (Lan-
kas et al., 1998). In these tissues, the transporters are thought to
play a role in protection against the cytotoxic effects of toxins
and xenobiotics (multiple drug resistance) by limiting toxin/
drug entry into certain tissues and promoting their elimination
into the bile and urine (Fromm, 2000).
The identification of cancer stem-like cells has further raised
the interest in the SP technique, and the SP phenotype might
explain the resistance of a subpopulation of tumor cells to
chemotherapy (Chua et al., 2008; Dean et al., 2005; Hirsch-
mann-Jax et al., 2004; Ling, 1995; Szotek et al., 2006; Wu
et al., 2007). SP cells have been identified in a number of cancers
where they have been shown to display increased capacity of
self-renewal and tumorigenicity when transplanted into immuno-
compromised mice (Bleau et al., 2009; Chiba et al., 2006;
Chua et al., 2008; Haraguchi et al., 2006; Ho et al., 2007; Mitsu-
take et al., 2007; Patrawala et al., 2005;Wu and Alman, 2008;Wu
et al., 2007). The percentage of SP cells in primary mesenchymal
tumors appears to correlate with tumor grade and has been
proposed as a predictor of patient outcome (Wu et al., 2007).
SP cells from colon and breast carcinoma display higher expres-
sion of stem-cell-related genes compared to non-SP cells (Har-
aguchi et al., 2006; Zhou et al., 2007). However, it should be
emphasized that, similar to normal tissues, not every cancer
contains SP cells. Therefore, SP cells may only represent one
of the putative cancer stem cell populations.
Thus, the SP assay constitutes a highly valuable primary puri-
fication strategy for isolating potential stem/progenitor cells from
Table 1. Overview of the SP Protocol
SP Protocol Steps Critical Parameters Proposed Data Reporting Details
(1) Cell/tissue extraction stable in vitro cell line culture conditions; fresh primary
tissue
type and origin of cell line/tissue; inbred animal strains
(2) Single-cell suspension optimized dissociation protocol; stable cell
concentration (nucleated cells)
type of dissociation protocol (type of instruments and
enzymes); dissociation conditions and time
(3) Hoechst dye efflux appropriate dye concentration; stable incubation
conditions (time, temperature, darkness); inhibition
controls
Hoechst or other dye concentration in SP test (if other
than recommended justification should be provided);
cell concentration in SP test; type and concentration of
efflux inhibitors
(4) Cell-surface phenotyping inhibition of cell metabolic activity (cold incubation
conditions); antibody type and concentration; dead
cell discrimination marker
(see Table 2 for published examples and references)
antibody clone and fluorochrome; antibody
concentration/dilution and staining conditions (time,
temperature)
(5) Data acquisition flow cytometer with a high power UV laser (50–100
mV); sensitive ‘Hoechst red’ channel detector; low
coefficients of variation (CVs); low sample pressure
(Hoechst profile in linear mode); high cell concentration
flow cytometer model used, shear pressure; laser
types and power used; emission wavelength,
specification of filters
(6) Data analysis gating strategy including: single-cell analysis with
debris exclusion; erythrocyte exclusion; dead cell
discrimination; inhibition controls; cell surface
phenotyping; cell ploidy
software package(s) used for analysis:
display of gating strategy, including percentage of
events in each gate; display of examples of gating
strategy on dot plots applied before SPgate, including
scale used (linear/log) and specification of the
population displayed on the plot; display of SP test and
inhibition controls to validate the SP gate; for SP cell
membrane phenotyping display of SP on phenotyping
plot and phenotyped population on Hoechst plot
(back-gating)
Chronological steps in the multicolor SP assay (left column) and associated critical parameters (middle column), as discussed in text. Right column:
recommendations of parameters to be included for data reporting of SP assay.
Cell Stem Cell
Protocol Reviewvarious tissues, particularly in the absence of specific cell-
surface markers. Nevertheless it is important to keep in mind
that in most tissues, the SP phenotype is not exclusive to stem
cells. While a number of detailed SP method protocols (Goodell,
2005; Goodell et al., 2005; Lin and Goodell, 2006; Petriz, 2007)
and reviews summarizing our knowledge of SP cells in different
tissues (e.g., Challen and Little, 2006; Schroeder, 2010; Wan
et al., 2010; Wu and Alman, 2008) have been published, here
we provide an overview of the principle and potential of the SP
assay and focus on the critical parameters that can challenge
the experimental design, conduct, and interpretation of results
when performing this assay. We highlight the value of combining
the SP assay with multicolor phenotyping, as well as the impact
of DNA ploidy on SP analysis, particularly in the context of
cancer stem-like cells. We also provide suggestions on how to
improve reproducibility of the SP analysis between laboratories
and how to standardize data reporting from SP assays. An over-
view of the SP protocol and the associated critical parameters is
provided in Table 1.
Principle, Potential, and Pitfalls of the SP Assay
In the early 1990s, it was shown that in vitro cultures of a subpop-
ulation of bone marrow cells are able to efflux fluorescent dyes,
such as Hoechst 33342 or Rhodamine 123 applied alone or in
combination (Li and Johnson, 1992; McAlister et al., 1990; Wolf
et al., 1993). Hoechst is a fluorescent dye that binds all nucleic
acidswith apreference for theAT-rich regionsof theminorgroove
of DNA (Lalande and Miller, 1979). Hoechst 33342, in contrast toHoechst 33258, can traverse the intact plasma membrane of
living cells. While uptake of the dye occurs uniformly in all cells
through passive diffusion, efflux is an active energy-driven
process. Only cells expressing a sufficient number of ABC trans-
porters are able to actively efflux the dye out of the cell.
Visualization of the Hoechst profile simultaneously in two
distinct channels of the flow cytometer, published first in 1996
by Goodell and colleagues, resulted in a significantly improved
resolution of the cell population with efflux properties (Goodell
et al., 1996). Optimal SP resolution requires a flow cytometer
equipped with an ultraviolet (UV) laser. Hoechst 33342, when
excited by UV light, emits fluorescence that can be detected in
two distinct channels on the flow cytometer: the ‘‘Hoechst
Blue’’ (450/50 nm band-pass filter) and the ‘‘Hoechst Red’’
(675/20 nm long-pass filter) channel, while a dichroic mirror
(LP635 nm) is used to split the emission wavelengths. As the
‘‘Hoechst Red’’ channel is more sensitive to small changes in
dye concentration, the so called ‘‘side population’’ (SP) cells
emerge as a distinct dim ‘‘tail’’ extending first on the left side
of G0/G1 cells (often referred to as the main population) toward
the lower ‘‘Hoechst Blue’’ signal (for example, see Figure 1), and
which is lost upon inhibition of ABC transporter activity. If a UV
laser is unavailable on the flow cytometer, Hoechst can also be
excited with non-UV wavelengths. However, in our experience,
neither Hoechst excitation by the near-UV or violet laser (Telford
and Frolova, 2004) nor the use of alternative non-UV excitable
DNA dyes (Telford et al., 2007) leads to the sharp SP resolution
as observed with traditional UV sources.Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc. 137
Figure 1. Gating Strategy for SP Data Analysis
An example of a step-by-step gating strategy and the resulting percentage of cell populations is shown for mouse bone marrow, a well-established example of
SP-containing tissue (Goodell et al., 1996; Lin and Goodell, 2006). Appropriate discrimination of single, viable, and nucleated cells is crucial for adequate char-
acterization of the SP.
(A) Gating strategy. (1) Cells are distinguished from debris on the flow-cytometric profile based on the Forward Scatter (FSC, related to the cell size) and Side
Scatter (SSC, related to cell granularity). (2) To assure that a detected signal arises from single cells, cell doublets and aggregates are gated out based on their
properties displayed on the SSC area (SSC-A) versus height (SSC-H) dot plot. (3) Dead cells are recognized by their strong positivity for the dead cell discrim-
ination marker. (4) Due to its function as a DNA-binding dye, the Hoechst dye fluorescence signal can be used to visualize cells in a specific phase of the cell cycle
(G0/G1, S, and G2/M) by indicating the DNA content per cell. The cell-cycle status of the major cell populations is highlighted by the dotted circles on the dot plot.
For cell suspensions from primary tissue, enucleated erythrocytes (marked in red) can be excluded by applying an additional ‘‘Hoechst’’ gate on the ‘‘Hoechst
Red’’/‘‘Hoechst Blue’’ dot plot in the linear scale. (5) SP cells are recognized as a dim tail extending first on the left side of G0/G1 cells toward the lower ‘‘Hoechst
Blue’’ signal. (6) Erythrocytes can also be recognized and gated as the Hoechst negative cell population on the ‘‘Hoechst Red’’ and/or ‘‘Hoechst blue’’ channel
displayed in the logarithmic scale.
(B) Gating tree. The gating tree indicates the sequential procedure applied to select out the final population for SP discrimination and the percentage of cells
(gated events) resulting from each gating step. ‘‘% Parent’’ indicates the percentage of gated events relative to the preceding gate, while ‘‘% Total’’ indicates
the percentage of gated events relative to all events recorded. The SP assay was performed according to the classical SP protocol (Goodell et al., 1996; Lin
and Goodell, 2006). Briefly, cells were resuspended in prewarmed DMEM, 2% FBS 10 mM HEPES (pH 7.4) (1 3 106 cells/ml nucleated cells). Samples were
incubated in the presence of 5 mg/ml Hoechst 33342 for 90 min at 37C with agitation in the dark, followed by rinsing in cold HBSS 2% FBS, 10 mM HEPES
(pH 7.4) buffer. All subsequent steps were done at 4C. The Near-IR Live/Dead marker (Invitrogen) was used for dead cell discrimination (30 min at 4C in the
dark). Data acquisition was performed at 4C with the FACS Aria SORP cytometer (BD Biosciences) using DIVA software. The analysis of bone marrow SP
does not differ betweenmouse strains; however, the exact percentage of SPmay vary according to the genetic background of themouse. Note that bonemarrow
isolated fromNOD/Scidmice (shown here) gives a higher percentage of SP (1.9%) compared to normal bonemarrow (0.3%–0.5%), because of the lack of mature
lymphocytes in these mice (Niclou et al., 2008).
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bolic process, it does not only serve as a positive/negative
marker for cell phenotyping, but carries additional information
about the functional status of the cells. It also has a significant
resolution advantage over classical immunostaining with anti-
bodies against ABC transporters. Due to its high sensitivity,
even rare SP events (<0.5% of the total cell population) can be
detected within heterogeneous samples. The combination of
the SP assay with cell surface phenotyping can lead to a further
characterization of putative stem cell and cancer stem cell
populations. Moreover, the SP assay, being performed on viable138 Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc.cell populations, enables subsequent functional characterization
of the cells in vitro and in vivo, which is not possible with many
other DNA-binding dyes.
In contrast to classical cell-surface staining protocols for
flow-cytometric analysis, the SP assay requires an additional
dye incubation step for the appropriate equilibration of the dye
between the extracellular and intracellular compartment prior
to dye efflux by cells expressing ABC transporters. ABC trans-
porter-mediated dye efflux is an active and dynamic biological
process and, thus, is highly sensitive to even slight modifications
in the staining procedure. This sensitivity can easily lead to
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laboratories, which have called into question the reliability of
the SP assay. However, we believe that insight into the critical
parameters of the assay (discussed in detail in the next para-
graphs) will allow the technique to be adopted by a larger
research community and to be applied to less well-studied
tissues (e.g., solid tissues, including tumors).Critical Parameters of the Side Population Protocol
Influence of Cell Integrity, Concentration,
and Erythrocyte Contamination
The preparation of a viable single cell suspension is a crucial step
in the SP assay. This goal is particularly challenging for solid
tissues requiring mechanical and/or enzymatic dissociation
steps which inevitably affects cell viability and protein integrity
at the cell surface. Therefore, dissociation protocols often
require adaptation for each tissue type, to achieve single cell
suspensions with minimal cellular damage. The culture condi-
tions of established cell lines may also influence the SP analysis.
Since the percentage of SP cells depends on cell density,
nutrient composition, serum and oxygen levels, it is advisable
to standardize the culture conditions between SP assays to
obtain reproducible results (Tavaluc et al., 2007).
In addition to viability, the cell concentration of the single-cell
suspension is another key parameter to be considered in the SP
protocol. Changing the cell number between samples and
experiments directly influences the equilibration of Hoechst
between the buffer and the intracellular compartment. Although
1 3 106 cells/ml per test is a standard concentration frequently
reported, it is important, when working with primary tissues,
that only viable and nucleated cells are counted in the reported
cell concentration. In highly vascularized tissue, such as bone
marrow or brain, the presence of erythrocytes will strongly influ-
ence the Hoechst equilibration and the percentage of SP cells re-
corded and should, therefore, not be included in the cell count. If
enucleated cells cannot be properly distinguished at the time of
sample analysis, erythrocyte cell lysis can be performed on
a small test sample to recalculate the ratio between nucleated
and enucleated cells. Erythrocyte lysis on the whole sample
preparation is possible using the classical lysis protocol, e.g.,
with ammonium chloride, but cannot be performed with most
of the commercially available lysis solutions, which cause cell
fixation. Nevertheless, as cell viability and cell number are
already compromised after tissue dissociation, we prefer to
avoid the lysis step. Also, any pre-enrichment technique,
including magnetic sorting, is not advisable for small-volume
samples because it may compromise cell number and viability.
A valuable alternative to mechanical or chemical separation
techniques is to first exclude erythrocytes from the cell count
prior to Hoechst staining and, second, from the analysis by im-
plementing an additional gate to select only nucleated cells
(example in Figure 1A, erythrocytes depicted in red). If present,
enucleated erythrocytes appear as negative events in the
‘‘Hoechst red’’ and ‘‘Hoechst blue’’ channels and can properly
be visualized if one of the Hoechst channels is displayed in the
logarithmic scale (Figure 1A). In this context, it is important to
realize that an adequate gating strategy during data analysis,
focusing on single, viable, nucleated cell populations, is crucialto reliably determine the presence and the percentage of the
SP (Figure 1).
Staining Protocol: Influence of Hoechst Concentration
and Hoechst Toxicity
The SP discrimination is also greatly affected by the concentra-
tion of Hoechst 33342 (Montanaro et al., 2004). As different dye
concentrations (3–20 mg/ml) are reported in the literature, a direct
comparison of results is often impossible. While 5 mg/ml Hoechst
is considered standard for most tissues, including bone marrow,
some tissues, such as muscle and skin, were found to require
a higher dye concentration for optimal SP resolution (Gussoni
et al., 1999; Montanaro et al., 2004). To increase the chance of
SP detection, researchers tend to decrease the concentration
of the dye, not realizing that cells with an unsaturated Hoechst
staining can be mistaken for SP cells (see example in
Figure 2A). Alternatively, in SP-containing tissues, non-SP cells
can be inappropriately included in the SP gate. On the other
hand, oversaturated Hoechst can lead to increased cell death,
poor resolution, or even total loss of the SP. For newly studied
tissues, we propose to perform Hoechst saturation and toxicity
dose response curves, with the optimal dye concentration lying
within a plateau region, where the percentage of SP cells is
stable (Figure 2A). Importantly, the Hoechst concentration curve
needs to be combined with transporter inhibition tests in order to
confirm the specificity of the dye efflux (see below).
A main pitfall of the SP assay is its high sensitivity to slight vari-
ations in staining conditions. Stable incubation conditions such
as temperature (37C), duration, and light conditions (darkness)
are essential for proper dye equilibration and to minimize cellular
toxicity. Although a range of incubation times have been re-
ported for different species, in our hands, no significant differ-
ence between SP discrimination and frequency was detected
for mouse and human cells (using incubation times between
90–120 min). In case of doubt, a time-course experiment can
be performed to assess the minimal incubation time required
for best SP discrimination. For adequate temperature control,
the Hoechst incubation step is classically carried out in a water
bath. In order to avoid manual mixing of the tubes, dye incuba-
tion can also be successfully performed in a 37C incubator
(e.g., tissue culture incubator) equipped with a gentle shaker.
Importantly, each step following the Hoechst staining, including
washing, centrifugation, antibody staining, and data acquisition,
should be performed in the cold (4C) and in the dark, thus mini-
mizing metabolic activity of the cells and preserving the Hoechst
profile.
As a DNA-binding molecule, Hoechst is toxic for cells, partic-
ularly at high concentrations. The toxic effect is even more
profound upon exposure to UV light. Therefore, another major
caveat of the SP assay is the effect of Hoechst staining on cell
survival after SP analysis and cell sorting. There is, at present,
a strong controversy regarding the clonogenic and tumorigenic
potential of stem cell/cancer stem cell SP and non-SP popula-
tions within cell lines, primary tissues, and tumor biopsies
(Adamski et al., 2007; Camargo et al., 2006; Wu et al., 2007;
Zheng et al., 2007; Zhou et al., 2007). The possibility that
increased clonogenicity of SP cells is based on their efflux
capacity leading to decreased Hoechst toxicity is difficult to
exclude. It has also been suggested that cell viability is minimally
affected by Hoechst at the concentration used but may, rather,Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc. 139
Figure 2. Critical Parameters in the SP Protocol
(A) Hoechst concentration. The importance of the appropriate Hoechst concentration for the reliable detection of the SP is shown for the MCF7 cells, a well-
established SP-containing cell line (Patrawala et al., 2005; Yin et al., 2008). Since the optimal dye concentration for best SP resolution may vary according to
the cell type analyzed (Montanaro et al., 2004), a Hoechst concentration curve can be performed (e.g., 2.5–12 mg/ml). Based on efflux inhibition controls
(data not shown), 5mg/ml of Hoechst is sufficient for dye saturation in these cells (SP1%). Decreasing the Hoechst concentration below 5 mg/ml leads to an
unsaturated Hoechst profile where non-SP cells are introduced in the SP gate (SPz 11%), while elevated Hoechst concentrations lead to reduced SP resolution
(SP < 0.2%). Only single viable cells are displayed on the dot plots.
140 Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc.
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Goodell et al., 1997). In view of this unresolved issue, we recom-
mend including functional viability assays in vitro or in vivo of any
isolated fractions in order to detect any confounding factors
related to dye toxicity and cell sorting.
Significance of ABC Inhibition Controls
A significant number of ABC transporter inhibitors is available,
which are characterized by different specificities toward distinct
ABC family members. Verapamil, cyclosporine A, and proben-
ecid target the ABCB1 protein (Potschka and Loscher, 2001),
while Fumitremorgin C (FTC) is highly specific in its ability to
block the ABCG2 protein (Rabindran et al., 2000; Yin et al.,
2008) because it exhibits minimal effect on ABCB1 and
ABCC1-5 transporters. Nevertheless, some of the inhibitors of
ABCB1 and ABCC1, such as imatinib, also inhibit ABCG2 activity
(Robey et al., 2009). Indeed, no selective inhibitor has been iden-
tified thus far that blocks the ABCC subfamily or its individual
members (Loscher and Potschka, 2005b).
Appropriate SP discrimination relies heavily on transporter
inhibition control experiments, particularly for very rare SP
events (0.1%–0.5%). The observed loss of SP following trans-
porter inhibition allows a confirmation of SP identity and
excludes any erroneous SP events. The high variability observed
in the published SP gating strategies and the lack of justification
thereof represents a major problem in the literature: in some
reports, the SP gate is placed close or even within the G0/G1
region (and/or apoptotic cells) while in others it is limited to the
low side of the SP. Transporter inhibition controls allow an
unequivocal definition of the boundary between the SP and
non-SP cell population, thereby justifying the gating strategy
(Figure 2B).
It should also be noted that dye efflux can be triggered by
several types of transporters expressed within the same cell or
within distinct subpopulations of the SP. For instance, the tissue
distribution of ABCG2 overlaps extensively with that of ABCB1,
and expression of different transporters has been detected
within the same tissues (reviewed in Robey et al., 2009; Schinkel
and Jonker, 2003; Sun et al., 2003; Zhou et al., 2001). Further-
more, ABC transporter expression changes during organ devel-
opment. For example, SP cells in the fetal brain are sensitive to
the ABCG2 inhibitor Ko143, whereas in the adult forebrain, the
SP is inhibited by the ABCB1 inhibitor verapamil, despite the
fact that both SP populations comprise mainly cells of endothe-
lial origin (Mouthon et al., 2006).
To ensure maximal transporter inhibition leading to a precise
adjustment of the SP gate, it is preferable to establish a dose-(B) Effux inhibition controls. An appropriate SP discrimination and gating requires c
inhibition tests with Fumitremorgin C (FTC) and verapamil is shown for brain tissue
verapamil (2mMand 100mM respectively) for 20min prior to and during Hoechst sta
inhibition is observed with verapamil. Co-incubation with the two inhibitors results
mined by more than one transporter. Importantly, the control with the strongest in
a ‘positive control’ by performing the inhibition tests simultaneously on a well de
(C) Debris and dead cell discrimination. To illustrate the importance of adequate de
in cell lines that do not contain SP cells (U87 and SF767 glioma cells) are shown. T
exclusion, (3) single-cell events after aggregate exclusion, and (4) single viable ce
for each population is displayed on each dot plot. Most of the putative SP even
whereas in SF767 cells, dead-cell discrimination is required to abolish inappro
may explain controversial results for U87 and other glioma cell lines reported i
2004; Patrawala et al., 2005). A uniform decrease of the signal in both Hoechst c
U87, arrow on dot plot 4). SF767 cells were obtained from the UCSF Tissue Banresponse curve for several inhibitors. If necessary, e.g., in poorly
defined tissues, this optimization step may even be conducted
with different Hoechst concentrations. Only those populations
showing decreased efflux properties upon inhibition can be
considered as a valid SP. If SP cells show sensitivity to several
inhibitors, controls containing a combination of two or more
chemicals can be applied (for example see Figure 2B). In the
presence of a heterogeneous SP, where cell subpopulations
react differently to varying inhibitors, the SP gate may be option-
ally divided into several subgates according to the separation
profile and the SP behavior in inhibition tests. In summary,
because of the high sensitivity of the SP protocol, it is highly
advisable to include inhibition controls in each experiment,
thus validating the specificity of the Hoechst profile obtained.
In addition, it is useful to include a well-defined SP model as
a positive control and validate the inhibition controls simulta-
neously in the known model and in the specific population of
interest.
Significance of Dead Cell Discrimination Prior
to SP Analysis
Adequate exclusion of dead cells is crucial for any flow-cytomet-
ric data analysis. Dead cells exhibit properties distinct from their
viable counterparts, such as unspecific antibody binding. The
Hoechst dye binds to all DNA, whether associated with live,
dead, or apoptotic cells or debris. Dead cells can inappropriately
appear as SP and, thus, an appropriate gating strategy plays an
essential role in defining the Hoechst profile of single, viable, and
nucleated cells (Figure 1). In many cases, dead-cell particles,
which could be mistaken for SP cells, can be gated out by debris
exclusion, as shown for the U87 cell line (Figure 2C) that does
not contain SP cells (Bleau et al., 2009). However, for other
SP-negative cell lines, additional dead-cell discrimination is
indispensable (e.g., SF767 cell line; Figure 2C) and can be easily
integrated in the SP analysis by application of an adequate dead-
cell discrimination marker.
Furthermore, during apoptosis, the cellular DNA content is
diminished, as degraded DNA leaks out during cell rinsing and
staining (Compton, 1992). Because some cell lines show a high
proportion of apoptotic cells, which display a uniform decrease
of the signal in both Hoechst channels, apoptotic cells can easily
bemistaken for SP cells (see, e.g., U87 cells in Figure 2C, arrow).
The original protocol developed by Goodell and colleagues for
bone marrow employed propidium iodide (PI) for dead-cell
discrimination. Although successfully used as a dead-cell
marker, PI is excited by the UV laser and is detected in the
‘‘Hoechst red’’ channel, giving rise to an additional PI signal inontrol experiments with one or more ABC transporter inhibitors. An example of
(see e.g., (Loscher and Potschka, 2005a)). Cells were incubated with FTC and
ining. FTC leads only to a partial inhibition of brain-derived SP, while significant
in full SP efflux inhibition, indicating that the efflux potential in brain SP is deter-
hibition effect is used for the final set up of the SP gate. It is advisable to include
fined SP model.
bris and dead cell discrimination on SP detection, two examples of SP analysis
he SP profile is displayed for (1) all events recorded, (2) cell events after debris
lls after dead-cell exclusion. The percentage of events displayed in the SP gate
ts in U87 cells can already be eliminated after appropriate debris exclusion,
priate SP events. Inadequate Hoechst concentrations and gating strategies
n the literature (Bleau et al., 2009; Chua et al., 2008; Hirschmann-Jax et al.,
hannels represents apoptotic cells which should not be mistaken for SP (see
k.
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Table 2. Examples of SP Phenotyping in Different Tissues
Tissue Type SP Cell Type Characterized Phenotyping Markers References
Bone marrow hematopoietic stem cells Lin Sca-1+ CD117+ CD34/low Flk2
CD45+ CD44+
Goodell et al. (1996); Camargo et al. (2006);
Lin and Goodell (2006); Challen et al. (2010)
Lung bone marrow-derived cells CD45+ CD34+ CD31+ ;
CD45 CD34 CD31+/
Summer et al. (2003); Summer et al. (2004)
Liver very heterogeneous bone
marrow-derived population
CD45+ CD34+ CD117+ Sca-1+ Thy1+;
CD45 CD34+ CD117+ Sca-1+ Thy1+
Wulf et al. (2003)
Skeletal
muscle
muscle stem cells;
bone marrow-derived cells
Lin Sca-1+ CD45;
Lin Sca-1+ CD45+
Asakura et al. (2002); Gussoni et al. (1999)
Testis testis stem cells CD45 CD34 Sca-1+ CD117+/ Lassalle et al. (2004); Falciatori et al. (2004)
Brain endothelial cells; astroglial cells;
microglia; fetal neural stem cells
CD31+ CD133+ CD45; A2B5+;
CD11b+; CD15+ CD133+ CD31
Mouthon et al. (2006)
Reports on multicolor phenotyping of SP populations from different tissues. In many tissues (lung, liver, muscle, brain) several cell types with different
phenotypic profiles were identified within the SP.
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researchers. Since PI is also excited by a blue laser, measuring
PI emission on a logarithmic scale using a different PMT
(BP630/30) has been recommended in order to achieve a more
precise discrimination of dead cells (Petriz, 2007). Recently,
novel dead-cell discrimination markers have been developed,
which are not excited by the UV laser and show a narrow range
of emission wavelength. In our experience, such markers,
including the newDNA-binding reagents (e.g., TO-PRO-3 iodide)
or cell membrane dyes (e.g., the LIVE/DEAD Fixable Dead Cell
Stains) are of a superior value for SP analysis, particularly in
combination with multicolor phenotyping.
Multicolor SP Phenotyping
A major challenge in stem cell biology is the identification of
specific cell-surface markers that unambiguously characterize
a given stem cell population. Although the dye efflux property
has been found to be a valid feature for isolating potential
stem/progenitor cells from various sources, the SP populations
are often heterogeneous. In several studies the combination of
the SP assay with additional phenotyping significantly increased
the purity of stem cells (references in Table 2). Multicolor pheno-
typing is becoming a standard in flow cytometry and can be
combined with the SP assay if the antibody staining is carried
out in the cold (4C). Such phenotyping provides essential infor-
mation as to the cellular subpopulations present within an iden-
tified SP. In Figure 3, we provide an example of the potential data
display for SP phenotyping in heterogeneous tissues, such as
the brain and bone marrow. In order to determine the heteroge-
neity of the SP, the distribution of SP cells can be shown within
the phenotyped cell population (e.g., Figure 3A). In addition,
the Hoechst profile can be displayed for the population of
interest to indicate the percentage of cells containing the dye
efflux property (e.g., Figure 3B). A ‘‘back-gating’’ of the pheno-
typed populations is useful to validate the gating strategy, as
small inadequate shifts in gating can significantly influence final
results. Moreover, as the prolonged SP protocol can lead to
instability of the Hoechst profile, studies addressing SP subpop-
ulations with multicolor phenotyping require efflux inhibition
tests in combination with the cell-surface staining (as in
Figure 2B). It should also be noted that within a heterogeneous142 Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc.SP where varying levels of ABC transporters are expressed,
different subpopulations can occupy distinct positions within
the SP gate, with certain cells exhibiting stronger efflux proper-
ties than others (Montanaro et al., 2004). In this case, dividing
the SP gate into subgates can be helpful.
Although potentially challenging, multicolor phenotyping of
the SP provides important critical information: first, as
mentioned earlier, the SPmay contain not only a uniform somatic
stem cell population, but also early progenitor cells, which may
have lost their stem cell potential and phenotypic signature but
kept the dye efflux property. For example, it has been shown
that cell surface phenotyping in the bone-marrow-derived SP
leads to further purification of the HSCs, excluding other
precursor cells and multipotential progenitors (Camargo et al.,
2006; Lin and Goodell, 2006). Second, the SP can contain
more than one stem cell population. In solid tissues, such as
lung, liver, or skeletal muscle, the SP has been found to be
very heterogeneous and includes not only resident stem cells
but also bone marrow derived stem cells (Asakura et al., 2002;
Summer et al., 2003, 2004; Wulf et al., 2003). The testis SP pop-
ulation has been found to consist of spermatogonial, germinal,
and mesenchymal stem cells (Falciatori et al., 2004; Lassalle
et al., 2004). Last but not least, in certain organs, ABC trans-
porter-expressing cells are not associated with stem cell proper-
ties. For example, in the brain, ABC transporters are widely
expressed in endothelial cells, where they play a major role in
the maintenance of the blood-brain barrier (Cooray et al., 2002;
Hori et al., 2004; Orford et al., 2009; Zhang et al., 2003). Indeed,
within fetal and adult brain, endothelial cells constitute the vast
majority of the SP population (Mouthon et al., 2006).
In summary, it is important to emphasize that ABC trans-
porters are not exclusive to stem cells, and the term ‘‘side
population cell’’ should not be equated with ‘‘stem cell.’’ Cell
surface multicolor phenotyping can provide important additional
clues on the identity of the SP cells. Also of interest in this respect
is the presence of internal markers or the cell-cycle profile of the
SP, which can, however, only be examined after sorting of the SP
cells. Obviously, in order to confirm the stem cell nature of phe-
notyped SP cells, downstream characterization at the functional
level is indispensable. Thus, the identification of bona fide stem
cells/cancer stem-like cells always requires in vitro and in vivo
Figure 3. Multicolor SP Phenotyping
Examples of multicolor phenotyping of the SP are displayed for mouse bone marrow and brain as reported, e.g., in Camargo et al. (2006), Lin and Goodell (2006),
and (Mouthon et al. (2006). The Hoechst profile (A) and the phenotyped profile (B) of single, viable, and nucleated cells is displayed.
(A) Heterogeneity within SP. To determine the heterogeneity of the SP, the gated SP events can be displayed on the phenotyped dot plot.
(B) Dye efflux property within phenotyped population. Conversely, the stained population of interest can also be shown on the Hoechst plot to indicate the propor-
tion of phenotyped cells that carry the dye efflux property. Importantly, the phenotyped SP subpopulations need to be further confirmed by inhibition controls.
(C) Gating tree: the gating trees of bone marrow and brain cell populations, indicating the appropriate percentage of cells within each gated population relative to
parent or total events. SP multicolor phenotyping (CD117/CD44) in bone marrow: 93.6% of bone marrow SP cells are CD117+CD44+, while CD117CD44+
represent only less than3.9%of bonemarrow SP (A). Importantly, CD117+CD44+ cells are heterogeneous, and only 25%of themdisplay the dye efflux property
(B). SP multicolor phenotyping (CD31/CD44) in brain tissue: 85.7% of brain-derived SP cells are CD31+CD44 corresponding to endothelial cells (A), and
92.5% of the CD31+CD44 cells display the dye efflux property (B). The SP protocol was as in Figure 1. Cells were subsequently incubated with antibody conju-
gates for 30 min at 4C in the dark (mCD117-PE Immunotools no. 22151173 10 ml/test; h/mCD44-PECy7 eBioscience no. 25-0441 1.2 ml/test; mCD31-APC BD
Bioscience no. 551262 5 ml/test), in the presence of the Near-IR Live/Dead marker (Invitrogen). Results were confirmed with inhibition controls combined with
antibody staining as outlined in Figure 2B.
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differentiation assays, engraftment into lethally irradiated mice,
or xenografts in immunocompromised animals.
Influence of Tumor/Host Populations and Cell Ploidy in
SP Analysis for Cancer Stem Cells
With a growing focus on cancer stem cell populations, the SP
discrimination assay has recently been used to assess the
presence of putative cancer stem cells in a variety of cancer
cell lines and primary tumors. Cancer research models are
not perfect, and each carries its own advantages and pitfalls.
For patient biopsies or animal models (xenografts or transgenic
models), flow-cytometric analysis, including the SP assay, is
often hampered by the heterogeneity of the sample and the
lack of distinction between tumor and normal cells (Bleau
et al., 2009; Harris et al., 2008). In the current literature, putative
cancer stem cells within tumor biopsies or xenografts are often
characterized with a limited number of phenotypic markers,
while neglecting that other differentiated cell populations or
stromal cells within a tumor can display similar phenotypic
properties. It is worth noting that SP cells within a tumor
mass do not always represent tumor cells but can arise from
stromal populations carrying dye efflux properties. For
example, in brain tumors derived from mouse models, the SP
is, similar to the normal brain, largely composed of mouse
endothelial cells, and the nonendothelial SP of mouse braintumors could be tumor and/or stroma derived (Bleau et al.,
2009; Mouthon et al., 2006) (see also Figure 3). Therefore,
a further characterization of the SP population detected within
a tumor mass, based on genotypic and phenotypic profiling, is
mandatory in order to confirm their cellular origin. In xenograft
models commonly used in cancer research, the discrimination
between transplanted tumor cells and normal host cells is
possible, though rarely done, either by phenotyping with
species-specific and/or cell type-specific antibodies or by
marking one population with a fluorescent label. In this respect,
the use of a GFP-expressing immunodeficient mouse model is
of great value (Niclou et al., 2008) (see also Figure 4). Compar-
ison of a tumor-derived SP with the Hoechst profile from
healthy tissue can also facilitate data interpretation, but it
should be kept in mind, though, that tumors attract many
different cell types, including endogenous stem cell populations
from distinct parts of the body. Gliomas, for example, which are
highly heterogeneous brain tumors, are known to recruit
different types of host cells, such as neural stem cells, mesen-
chymal stem cells, and endothelial cells (Bjerkvig et al., 2009;
Ziu et al., 2006). Moreover, the aberrant composition of the
hematopoietic system in immunocompromised mouse models
used in cancer research, such as Nude, NOD/Scid, or NOG
mice, needs to be taken into account because these mice
lack certain differentiated cell types, such as mature lympho-
cytes (Niclou et al., 2008).Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc. 143
Figure 4. Influence of Graft/Host Populations and DNA Ploidy in the SP Analysis
In xenografted cancer models the discrimination between grafted (tumor) cells and endogenous host (stromal) cells is crucial for SP analysis, since both cell pop-
ulations can include cells with SP and/or stem cell properties. The heterogeneity of tumor samples (tumor versus stromal cells) needs to be taken into account
also in patient biopsies and in transgenic animal models. An example of the SP analysis is shown for an orthotopic glioma xenograft (U87 cells) in the eGFP ex-
pressing NOD/Scid mouse (as in (Niclou et al., 2008)). SP cells of gliomas are known to express both endothelial and stem cell markers, whereas U87 cells do not
possess SP properties (Bleau et al., 2009).
(A) Gating strategy for xenografted tumor samples. (1) Highly heterogeneous Hoechst profile are displayed within single, viable, and nucleated cells of the tumor
mass. (2) Human tumor cells are recognized as the eGFP population of relatively big cells compared to the eGFP+ mouse host cells. Tumor (black) and host
(green) populations displayed on the Hoechst dot plot suggest that the two populations display different levels of ploidy. (3) The DNA histograms visualize
the aneuploidy of tumor cells (U87; Clark et al., 2010) and the normal diploid profile of mouse stromal cells. The overlap of the tumor G0/G1 cells with the
G2/M mouse population is responsible for the overlap on the Hoechst SP profile plot. See also Figure 1 for cell-cycle status visualized on dot plots. After segre-
gation, the appropriate SP gates are adjusted for the tumor and host populations according to their ploidy. The SP should be expected as a distinct tail appearing
next to the G0/G1 population, regardless of their ploidy level. The possibility to distinguish tumor (black) from stromal cells (green) clearly shows that in this
example all SP cells are derived from the host tissue (37% of host cells).
(B) Gating tree. The gating tree indicates the percentage of cells within each gated population relative to parent or total events.
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research can arise from varying ploidieswithin tumor cells under-
going clonal selection. Because Hoechst fluorescence intensity
correlates with the DNA content of the cell and the chromatin
structure, it can distinguish different stages of the cell cycle as
well as distinct ploidies within a tumor mass (Arndt-Jovin and Jo-
vin, 1977). Blood and bone marrow consist of mononuclear and144 Cell Stem Cell 8, February 4, 2011 ª2011 Elsevier Inc.polynuclear cells, displaying a characteristic Hoechst profile
(see, e.g., Figure 1). Cancer cells often exhibit aneuploid popula-
tions, leading to a more heterogeneous Hoechst profile and
a misinterpretation of the SP assay results. Therefore, we
propose to assess the DNA content of tumor cells within the
SP assay and adjust SP gates appropriately according to the
ploidy of the cells. An example of such a SP gating strategy
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Protocol Reviewapplied to a xenograft tumor is presented in Figure 4, where
within the tumor mass normal diploid stromal cells can be segre-
gated from aneuploid tumor cells.
To summarize, tumor samples consist of heterogeneous cell
populations, including tumor and stromal cells. Therefore, the
discrimination between tumor and stromal cells within an SP
analysis may lead to a better understanding of the efflux property
within the tumor mass and its role in chemoresistance during
treatment. Furthermore, it is advisable to consider the cell ploidy
during data analysis of the Hoechst profile, as separate SP gates
may need to be applied for diploid and aneuploid cells. If the
discrimination is not possible based on marker expression or
on ploidy (e.g., diploid tumors), SP cells can be sorted and tested
for the presence of genetic aberrations associated with tumor
cells, followed by functional assessement with in vitro and
in vivo assays confirming their tumorigenic origin.
Data Reporting of SP Assay Results
Flow cytometry, including the SP assay, depends on stringent
protocol optimization in order to achieve maximum validity
and reproducibility, and efforts have been made recently to
standardize the reporting of flow-cytometry-based results in
peer-reviewed publications (Alexander et al., 2009; Lee et al.,
2008). Since the SP protocol often requires appropriate adapta-
tions for different tissues and species, we believe that standard-
izing the reporting of data can help to improve comparisons
between laboratories. We, therefore, propose a list of parame-
ters related to cell preparation and staining, data acquisition,
and analysis that could be included in the methods section of
publications (summarized in Table 1). Although there are well-
defined populations used in different research centers, the
protocol details can vary across laboratories, making results
challenging to compare across publications. More specifically,
as different enzymatic dissociation procedures can introduce
variability to the SP analysis, inclusion of protocol details on
the generation of cell suspensions is useful. Because of the
high sensitivity of the assay to dye staining conditions, details
on the Hoechst staining procedure should be provided. More-
over, as for any antibody-based method, it is advisable to
provide precise information on the antibody (as recommended
in Alexander et al. [2009]) because a small change, e.g., in the
antibody concentration, can potentially lead to a very different
outcome. Therefore, we emphasize the importance of providing
precise information on Hoechst and antibody staining conditions
as well as gating strategies to facilitate the comparison of data
between reports. Importantly, in order to standardize the data
reported by different laboratories, we also recommend adding
essential parameters of the flow cytometer instrument and
settings used for data acquisition. In this Protocol Review, we
present examples of possible data analysis and display for publi-
cations (Figures 1–4). Most importantly, a clear outline of the
gating hierarchy during SP data analysis (exemplified in Figure 1)
and appropriate justification by inhibition controls can strongly
improve the reliability of the assay and the comparison of results
between laboratories.
Concluding Remarks
During recent years the SP assay has proven to be an extremely
valuable approach for the characterization and isolation of puta-tive stem cell and cancer stem cell populations, particularly in the
absence of specific markers. Due to its high sensitivity, it allows
the detection of very rare events within heterogeneous cell pop-
ulations. However, the exponential increase in stem cell and
cancer stem cell research in recent years has led to a large
amount of reported SP assay data with sometimes questionable
interpretations. The dynamic nature of the dye efflux property,
relying on an intact cell metabolism, results in greater technical
variations in the determination and quantification of SP cells
than direct immunopurification procedures. In this Protocol
Review, we provide suggestions on how to improve the reliability
and reproducibility of the SP assay, with a particular focus on SP
protocol optimization, adequate controls for all parameters, and
addressing the heterogeneity of SP populations by multicolor
phenotyping and functional assays. We emphasize the chal-
lenges of SP analysis in cancer stem cell research with regard
to discrimination of tumor and stromal cell compartments and
diploid versus aneuploid cell populations. Finally, standardizing
the reporting of data, rather than standardizing the protocol,
may provide significant benefit to the scientific community in
the interpretation of SP results.REFERENCES
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